Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease
To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD). In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome me...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 2010-09, Vol.33 (5), p.260-264 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 264 |
|---|---|
| container_issue | 5 |
| container_start_page | 260 |
| container_title | Clinical neuropharmacology |
| container_volume | 33 |
| creator | Lundin, Anders Dietrichs, Espen Haghighi, Sara Göller, Marie-Louise Heiberg, Arvid Loutfi, Ghada Widner, Håkan Wiktorin, Klas Wiklund, Leif Svenningsson, Anders Sonesson, Clas Waters, Nicholas Waters, Susanna Tedroff, Joakim |
| description | To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD).
In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed.
There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P < 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo.
Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted. |
| doi_str_mv | 10.1097/WNF.0b013e3181ebb285 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_550263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>755948357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-279cf133edd3ff4662410695c5ae406ba28edcd9f345b9c65a2647fcec78ce253</originalsourceid><addsrcrecordid>eNqNkttqFEEQhgdRzBp9A5G-i4IT-3y4XNbECIuKeLpr-rhpnZ2ZTM8QNk-fXnYTQVj1ouim6vurqpu_qp4jeIqgEm--fzg_hRYiEgiSKFiLJXtQzRAjokYc_3hYzSDhuGac06PqSc4_IYRSUfW4OsKQIy6gmFXNWYzJGbcBpvUgmxjGDegiGC8D8F1v1qkNwyo5kEdjU5NuwgA-DamUki8l8HK--Iz4K5Ba0JsxhXbM4DqNl-BiasfUrsauPcnApxxMDk-rR9E0OTzbn8fV1_OzL4uLevnx3fvFfFk7DsVYY6FcRIQE70mMlHNMEeSKOWYChdwaLIN3XkVCmVWOM4M5FdEFJ6QLmJHjqt71zdehn6zuh7Q2w0Z3Jul96le5Bc0YxJwUXh3k-6Hzv0V3QoQRwVBCWrTLg9pm6kvYElsNF9ZKioT2QiJNjVBaCku0cZ57gVyEwf919VVpV1KrabeBQAgW_vVB_m36NtfdsNLTpBGhEpL_xNeTphir7eNOdnj5hasp5FGvU3ahaUwbuilrCQWWHDL1T1IwpqgkTBSS7kg3dDkPId4vgaDeOlsXZ-s_nV1kL_YDJrsO_l50Z2VyC1SQ-Gw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755948357</pqid></control><display><type>article</type><title>Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Lundin, Anders ; Dietrichs, Espen ; Haghighi, Sara ; Göller, Marie-Louise ; Heiberg, Arvid ; Loutfi, Ghada ; Widner, Håkan ; Wiktorin, Klas ; Wiklund, Leif ; Svenningsson, Anders ; Sonesson, Clas ; Waters, Nicholas ; Waters, Susanna ; Tedroff, Joakim</creator><creatorcontrib>Lundin, Anders ; Dietrichs, Espen ; Haghighi, Sara ; Göller, Marie-Louise ; Heiberg, Arvid ; Loutfi, Ghada ; Widner, Håkan ; Wiktorin, Klas ; Wiklund, Leif ; Svenningsson, Anders ; Sonesson, Clas ; Waters, Nicholas ; Waters, Susanna ; Tedroff, Joakim</creatorcontrib><description>To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD).
In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed.
There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P < 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo.
Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted.</description><identifier>ISSN: 0362-5664</identifier><identifier>ISSN: 1537-162X</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/WNF.0b013e3181ebb285</identifier><identifier>PMID: 20616707</identifier><language>eng</language><publisher>United States</publisher><subject>ACR16 ; Affective Symptoms - drug therapy ; Affective Symptoms - psychology ; Anxiety - drug therapy ; Anxiety - psychology ; Basic Medicine ; Cognition - drug effects ; Cognition - physiology ; Dopamine - metabolism ; Dopamine Antagonists - therapeutic use ; Dopamine D2 Receptor Antagonists ; dopaminergic stabilizer ; Double-Blind Method ; Farmakologi och toxikologi ; Female ; Humans ; Huntington Disease - drug therapy ; Huntington Disease - psychology ; Huntington's disease ; Male ; MEDICAL AND HEALTH SCIENCES ; MEDICIN ; MEDICIN OCH HÄLSOVETENSKAP ; MEDICINE ; Medicinska och farmaceutiska grundvetenskaper ; Middle Aged ; Pharmacology and Toxicology ; Piperidines - therapeutic use ; pridopidine ; randomized clinical trial ; Receptors, Dopamine D2 - metabolism ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Clinical neuropharmacology, 2010-09, Vol.33 (5), p.260-264</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-279cf133edd3ff4662410695c5ae406ba28edcd9f345b9c65a2647fcec78ce253</citedby><cites>FETCH-LOGICAL-c607t-279cf133edd3ff4662410695c5ae406ba28edcd9f345b9c65a2647fcec78ce253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20616707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-42294$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-134803$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/127110$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/1645157$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:121320804$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Lundin, Anders</creatorcontrib><creatorcontrib>Dietrichs, Espen</creatorcontrib><creatorcontrib>Haghighi, Sara</creatorcontrib><creatorcontrib>Göller, Marie-Louise</creatorcontrib><creatorcontrib>Heiberg, Arvid</creatorcontrib><creatorcontrib>Loutfi, Ghada</creatorcontrib><creatorcontrib>Widner, Håkan</creatorcontrib><creatorcontrib>Wiktorin, Klas</creatorcontrib><creatorcontrib>Wiklund, Leif</creatorcontrib><creatorcontrib>Svenningsson, Anders</creatorcontrib><creatorcontrib>Sonesson, Clas</creatorcontrib><creatorcontrib>Waters, Nicholas</creatorcontrib><creatorcontrib>Waters, Susanna</creatorcontrib><creatorcontrib>Tedroff, Joakim</creatorcontrib><title>Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD).
In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed.
There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P < 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo.
Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted.</description><subject>ACR16</subject><subject>Affective Symptoms - drug therapy</subject><subject>Affective Symptoms - psychology</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - psychology</subject><subject>Basic Medicine</subject><subject>Cognition - drug effects</subject><subject>Cognition - physiology</subject><subject>Dopamine - metabolism</subject><subject>Dopamine Antagonists - therapeutic use</subject><subject>Dopamine D2 Receptor Antagonists</subject><subject>dopaminergic stabilizer</subject><subject>Double-Blind Method</subject><subject>Farmakologi och toxikologi</subject><subject>Female</subject><subject>Humans</subject><subject>Huntington Disease - drug therapy</subject><subject>Huntington Disease - psychology</subject><subject>Huntington's disease</subject><subject>Male</subject><subject>MEDICAL AND HEALTH SCIENCES</subject><subject>MEDICIN</subject><subject>MEDICIN OCH HÄLSOVETENSKAP</subject><subject>MEDICINE</subject><subject>Medicinska och farmaceutiska grundvetenskaper</subject><subject>Middle Aged</subject><subject>Pharmacology and Toxicology</subject><subject>Piperidines - therapeutic use</subject><subject>pridopidine</subject><subject>randomized clinical trial</subject><subject>Receptors, Dopamine D2 - metabolism</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0362-5664</issn><issn>1537-162X</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkttqFEEQhgdRzBp9A5G-i4IT-3y4XNbECIuKeLpr-rhpnZ2ZTM8QNk-fXnYTQVj1ouim6vurqpu_qp4jeIqgEm--fzg_hRYiEgiSKFiLJXtQzRAjokYc_3hYzSDhuGac06PqSc4_IYRSUfW4OsKQIy6gmFXNWYzJGbcBpvUgmxjGDegiGC8D8F1v1qkNwyo5kEdjU5NuwgA-DamUki8l8HK--Iz4K5Ba0JsxhXbM4DqNl-BiasfUrsauPcnApxxMDk-rR9E0OTzbn8fV1_OzL4uLevnx3fvFfFk7DsVYY6FcRIQE70mMlHNMEeSKOWYChdwaLIN3XkVCmVWOM4M5FdEFJ6QLmJHjqt71zdehn6zuh7Q2w0Z3Jul96le5Bc0YxJwUXh3k-6Hzv0V3QoQRwVBCWrTLg9pm6kvYElsNF9ZKioT2QiJNjVBaCku0cZ57gVyEwf919VVpV1KrabeBQAgW_vVB_m36NtfdsNLTpBGhEpL_xNeTphir7eNOdnj5hasp5FGvU3ahaUwbuilrCQWWHDL1T1IwpqgkTBSS7kg3dDkPId4vgaDeOlsXZ-s_nV1kL_YDJrsO_l50Z2VyC1SQ-Gw</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Lundin, Anders</creator><creator>Dietrichs, Espen</creator><creator>Haghighi, Sara</creator><creator>Göller, Marie-Louise</creator><creator>Heiberg, Arvid</creator><creator>Loutfi, Ghada</creator><creator>Widner, Håkan</creator><creator>Wiktorin, Klas</creator><creator>Wiklund, Leif</creator><creator>Svenningsson, Anders</creator><creator>Sonesson, Clas</creator><creator>Waters, Nicholas</creator><creator>Waters, Susanna</creator><creator>Tedroff, Joakim</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D93</scope><scope>DF2</scope><scope>F1U</scope><scope>D95</scope></search><sort><creationdate>20100901</creationdate><title>Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease</title><author>Lundin, Anders ; Dietrichs, Espen ; Haghighi, Sara ; Göller, Marie-Louise ; Heiberg, Arvid ; Loutfi, Ghada ; Widner, Håkan ; Wiktorin, Klas ; Wiklund, Leif ; Svenningsson, Anders ; Sonesson, Clas ; Waters, Nicholas ; Waters, Susanna ; Tedroff, Joakim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-279cf133edd3ff4662410695c5ae406ba28edcd9f345b9c65a2647fcec78ce253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>ACR16</topic><topic>Affective Symptoms - drug therapy</topic><topic>Affective Symptoms - psychology</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - psychology</topic><topic>Basic Medicine</topic><topic>Cognition - drug effects</topic><topic>Cognition - physiology</topic><topic>Dopamine - metabolism</topic><topic>Dopamine Antagonists - therapeutic use</topic><topic>Dopamine D2 Receptor Antagonists</topic><topic>dopaminergic stabilizer</topic><topic>Double-Blind Method</topic><topic>Farmakologi och toxikologi</topic><topic>Female</topic><topic>Humans</topic><topic>Huntington Disease - drug therapy</topic><topic>Huntington Disease - psychology</topic><topic>Huntington's disease</topic><topic>Male</topic><topic>MEDICAL AND HEALTH SCIENCES</topic><topic>MEDICIN</topic><topic>MEDICIN OCH HÄLSOVETENSKAP</topic><topic>MEDICINE</topic><topic>Medicinska och farmaceutiska grundvetenskaper</topic><topic>Middle Aged</topic><topic>Pharmacology and Toxicology</topic><topic>Piperidines - therapeutic use</topic><topic>pridopidine</topic><topic>randomized clinical trial</topic><topic>Receptors, Dopamine D2 - metabolism</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lundin, Anders</creatorcontrib><creatorcontrib>Dietrichs, Espen</creatorcontrib><creatorcontrib>Haghighi, Sara</creatorcontrib><creatorcontrib>Göller, Marie-Louise</creatorcontrib><creatorcontrib>Heiberg, Arvid</creatorcontrib><creatorcontrib>Loutfi, Ghada</creatorcontrib><creatorcontrib>Widner, Håkan</creatorcontrib><creatorcontrib>Wiktorin, Klas</creatorcontrib><creatorcontrib>Wiklund, Leif</creatorcontrib><creatorcontrib>Svenningsson, Anders</creatorcontrib><creatorcontrib>Sonesson, Clas</creatorcontrib><creatorcontrib>Waters, Nicholas</creatorcontrib><creatorcontrib>Waters, Susanna</creatorcontrib><creatorcontrib>Tedroff, Joakim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Umeå universitet</collection><collection>SWEPUB Uppsala universitet</collection><collection>SWEPUB Göteborgs universitet</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lundin, Anders</au><au>Dietrichs, Espen</au><au>Haghighi, Sara</au><au>Göller, Marie-Louise</au><au>Heiberg, Arvid</au><au>Loutfi, Ghada</au><au>Widner, Håkan</au><au>Wiktorin, Klas</au><au>Wiklund, Leif</au><au>Svenningsson, Anders</au><au>Sonesson, Clas</au><au>Waters, Nicholas</au><au>Waters, Susanna</au><au>Tedroff, Joakim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>33</volume><issue>5</issue><spage>260</spage><epage>264</epage><pages>260-264</pages><issn>0362-5664</issn><issn>1537-162X</issn><eissn>1537-162X</eissn><abstract>To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease (HD).
In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington's Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed.
There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P < 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo.
Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted.</abstract><cop>United States</cop><pmid>20616707</pmid><doi>10.1097/WNF.0b013e3181ebb285</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 2010-09, Vol.33 (5), p.260-264 |
| issn | 0362-5664 1537-162X 1537-162X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_550263 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | ACR16 Affective Symptoms - drug therapy Affective Symptoms - psychology Anxiety - drug therapy Anxiety - psychology Basic Medicine Cognition - drug effects Cognition - physiology Dopamine - metabolism Dopamine Antagonists - therapeutic use Dopamine D2 Receptor Antagonists dopaminergic stabilizer Double-Blind Method Farmakologi och toxikologi Female Humans Huntington Disease - drug therapy Huntington Disease - psychology Huntington's disease Male MEDICAL AND HEALTH SCIENCES MEDICIN MEDICIN OCH HÄLSOVETENSKAP MEDICINE Medicinska och farmaceutiska grundvetenskaper Middle Aged Pharmacology and Toxicology Piperidines - therapeutic use pridopidine randomized clinical trial Receptors, Dopamine D2 - metabolism Severity of Illness Index Treatment Outcome |
| title | Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A16%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20the%20dopaminergic%20stabilizer%20Pridopidine%20(ACR16)%20in%20patients%20with%20Huntington's%20disease&rft.jtitle=Clinical%20neuropharmacology&rft.au=Lundin,%20Anders&rft.date=2010-09-01&rft.volume=33&rft.issue=5&rft.spage=260&rft.epage=264&rft.pages=260-264&rft.issn=0362-5664&rft.eissn=1537-162X&rft_id=info:doi/10.1097/WNF.0b013e3181ebb285&rft_dat=%3Cproquest_swepu%3E755948357%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755948357&rft_id=info:pmid/20616707&rfr_iscdi=true |